Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Acute Interstitial Pneumonia (AIP)

Acute interstitial pneumonia (AIP) distinctively stands out in interstitial lung diseases due to its sudden onset and acutely progressive nature, which often lands individuals with this rare disease in situations of dire respiratory distress. Our company, with its fortified standing in rare disease diagnosis and therapeutic development, can support your research of AIP pathogenesis and therapeutic research.

Introduction to AIP

Acute interstitial pneumonia (AIP) is a rare and idiopathic lung disease, also known as Hamman-Rich syndrome. The annual incidence of AIP ranges from 1 to 9 cases per 100,000 individuals per year and the mortality rate is higher than 50%. AIP is primarily targeting the microscopic regions of the lungs, known as the interstitium which is the prime region of gas exchange between tiny air sacs, the alveoli, and the bloodstream.

The molecular mechanisms of AIP.Fig.1 Molecular key players and signaling pathway characterizing the lung niche of idiopathic interstitial pneumonia individuals. (Samarelli, A. V., et al., 2021)

Pathogenesis of AIP

The pathogenesis of AIP involves a combination of immune dysregulation, lung injury, and abnormal repair processes. Injury to the lung epithelium leads to inflammation and scarring in the lung tissue (also known as fibrosis). AIP is characterized by excessive deposition of collagen and irreversible fibrosis, which can impair lung function and lead to respiratory failure.

Therapeutics of AIP

AIP is primarily managed with supportive care, but the use of medications can be considered based on the individual's presentation and the judgment of healthcare professionals. Small molecule drugs can be used in the therapeutic of AIP to improve symptoms and manage the condition.

  • Antibiotics
    Antibiotics such as ceftriaxone and clarithromycin may be used to treat or prevent bacterial infections that can occur as complications in individuals with AIP.
  • Immunosuppressants
    Immunosuppressive drugs like cyclophosphamide or azathioprine may be utilized to dampen the immune response and reduce inflammation in the lungs.
  • Corticosteroids
    Corticosteroids (such as prednisolone) have potent anti-inflammatory properties and can help reduce lung inflammation and symptoms.

Our Services

Our company is equipped with our vast experience in battling rare diseases and provides services in AIP research through all phases including animal models and therapeutic platform development, which can comprehensively support expansive research on AIP's pathogenesis and therapeutic development.

Platforms of AIP Therapy Development

Animal Models of AIP

The animal models can provide important insights into the mechanism of rare diseases such as AIP. Our company can develop animal models of AIP through physical or chemical induction to simulate inflammation and fibrosis in AIP individuals to support your study of the mechanisms behind the disease.

Chemical-induced Models
Intratracheal instillation or inhalation of bleomycin or lipopolysaccharide (LPS) in animals can lead to inflammation, epithelial cell injury and subsequent fibrosis of lung tissue, resulting in pathological features similar to AIP.
Optional Models
  • LPS induced model
  • Bleomycin induced model
Physical-induced Models
In mice and rats, high-dose whole thorax radiation exposure can lead to a delayed onset of a progressive lung injury resembling a fibrosing alveolitis similar to the pattern of injury seen in a subset of individuals with AIP.
Optional Models
  • Radiation-induced model
Optional Species Mice, Rats, Non-Human Primates, Others

Our company stands at the forefront of rare diseases, which can provide you with the relevant services required for each research stage of AIP disease to support your pharmacokinetics analysis and drug safety evaluation, promoting the pathogenesis research of AIP and the development of innovative therapies.

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Mrad, Ali. and Najia Huda. "Acute Interstitial Pneumonia." StatPearls (2023).
  • Samarelli, Anna Valeria et al. "Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players." International journal of molecular sciences 22.16 (2021): 8952.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.